{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:59Z","timestamp":1747181159747,"version":"3.40.5"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) have been hypothesized to benefit patients with COVID-19 via the inhibition of viral entry and other mechanisms. We conducted an individual participant data (IPD) meta-analysis assessing the effect of starting the ARB losartan in recently hospitalized COVID-19 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched ClinicalTrials.gov in January 2021 for U.S.\/Canada-based trials where an angiotensin-converting enzyme inhibitors\/ARB was a treatment arm, targeted outcomes could be extrapolated, and data sharing was allowed. Our primary outcome was a 7-point COVID-19 ordinal score measured 13 to 16 days post-enrollment. We analyzed data by fitting multilevel Bayesian ordinal regression models and standardizing the resulting predictions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>325 participants (156 losartan vs 169 control) from 4 studies contributed IPD. Three were randomized trials; one used non-randomized concurrent and historical controls. Baseline covariates were reasonably balanced for the randomized trials. All studies evaluated losartan. We found equivocal evidence of a difference in ordinal scores 13-16 days post-enrollment (model-standardized odds ratio [OR] 1.10, 95% credible interval [CrI] 0.76\u20131.71; adjusted OR 1.15, 95% CrI 0.15\u20133.59) and no compelling evidence of treatment effect heterogeneity among prespecified subgroups. Losartan had worse effects for those taking corticosteroids at baseline after adjusting for covariates (ratio of adjusted ORs 0.29, 95% CrI 0.08\u20130.99). Hypotension serious adverse event rates were numerically higher with losartan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In this IPD meta-analysis of hospitalized COVID-19 patients, we found no convincing evidence for the benefit of losartan versus control treatment, but a higher rate of hypotension adverse events with losartan.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033904","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T14:18:35Z","timestamp":1686320315000},"page":"e33904","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Losartan in hospitalized patients with COVID-19 in North America: An individual participant data meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8366-9882","authenticated-orcid":false,"given":"Leon","family":"Di Stefano","sequence":"first","affiliation":[{"name":"Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malathi","family":"Ram","sequence":"additional","affiliation":[{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"},{"name":"Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel O.","family":"Scharfstein","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianjing","family":"Li","sequence":"additional","affiliation":[{"name":"University of Colorado Denver, Anschutz Medical Campus, Denver, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeti","family":"Khanal","sequence":"additional","affiliation":[{"name":"Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheriza N.","family":"Baksh","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nichol","family":"McBee","sequence":"additional","affiliation":[{"name":"Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles D.","family":"Bengtson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Kansas Medical Center, KS City, KS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Gadomski","sequence":"additional","affiliation":[{"name":"Bassett Research Institute, Bassett Medical Center, Cooperstown, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Geriak","sequence":"additional","affiliation":[{"name":"Department of Research, Sharp Healthcare, San Diego, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Puskarich","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Minnesota, Minneapolis, MN"},{"name":"Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias A.","family":"Salathe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Kansas Medical Center, KS City, KS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aletta E.","family":"Schutte","sequence":"additional","affiliation":[{"name":"School of Population Health, University of New South Wales, The George Institute for Global Health, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Tignanelli","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Victory","sequence":"additional","affiliation":[{"name":"Bassett Research Institute, Bassett Medical Center, Cooperstown, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara E.","family":"Bierer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Hanley","sequence":"additional","affiliation":[{"name":"Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2219-6900","authenticated-orcid":false,"given":"Daniel A.","family":"Freilich","sequence":"additional","affiliation":[{"name":"Bassett Research Institute, Bassett Medical Center, Cooperstown, NY"},{"name":"Department of Internal Medicine, Division of Infectious Diseases, Bassett Medical Center, Cooperstown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Pandemic Response COVID-19 Research Collaboration Platform for ACEi\/ARB Pooled Analyses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2000912","DOI":"10.1183\/13993003.00912-2020","article-title":"Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.","volume":"56","author":"Ingraham","year":"2020","journal-title":"Eur Respir J"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S2213-2600(20)30153-3","article-title":"Antihypertensive drugs and risk of COVID-19?","volume":"8","author":"Tignanelli","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19.","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19.","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of COVID-19.","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19).","volume":"5","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ejhf.1924","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.","volume":"22","author":"Bean","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jama.2020.11301","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality.","volume":"324","author":"Fosb\u00f8l","year":"2020","journal-title":"JAMA"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1017\/cts.2020.489","article-title":"Safety of ACE-I and ARB medications in COVID-19: a retrospective cohort study of inpatients and outpatients in California.","volume":"5","author":"Rubin","year":"2021","journal-title":"J Clin Transl Sci"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial.","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","article-title":"Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial.","volume":"37","author":"Duarte","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40121-021-00453-3","article-title":"Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia.","volume":"10","author":"Geriak","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"630209","DOI":"10.3389\/fmed.2021.630209","article-title":"An open label trial to assess safety of losartan for treating worsening respiratory illness in COVID-19.","volume":"8","author":"Bengtson","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China.","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"100968","DOI":"10.1016\/j.conctc.2022.100968","article-title":"COVID MED \u2013 an early pandemic trial of losartan for hospitalized COVID-19 patients.","volume":"29","author":"Freilich","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"100957","DOI":"10.1016\/j.eclinm.2021.100957","article-title":"A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19.","volume":"37","author":"Puskarich","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e222735","DOI":"10.1001\/jamanetworkopen.2022.2735","article-title":"Efficacy of losartan in hospitalized patients with COVID-19-induced lung injury: a randomized clinical trial.","volume":"5","author":"Puskarich","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"e0273526","DOI":"10.1371\/journal.pone.0273526","article-title":"Pandemic Response COVID-19 Research Collaboration Platform for HCQ\/CQ Pooled Analyses. Hydroxychloroquine\/chloroquine for the treatment of hospitalized patients with COVID-19: an individual participant data meta-analysis.","volume":"17","author":"Di Stefano","year":"2022","journal-title":"PLoS One"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 \u2013 final report.","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research.","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: an R package for Bayesian multilevel models using stan.","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Soft"},{"key":"R25-20250504","first-page":"1","article-title":"micemultivariate imputation by chained equations in R.","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Soft"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s11222-016-9696-4","article-title":"Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC.","volume":"27","author":"Vehtari","year":"2017","journal-title":"Stat Comput"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R30-20250504","first-page":"115","article-title":"Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial.","volume":"182","author":"Ortigoza","year":"2022","journal-title":"\u1e45"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"e026143","DOI":"10.1161\/JAHA.122.026143","article-title":"Renin-angiotensin system inhibitors in patients with COVID-19: a meta-analysis of randomized controlled trials led by the International Society of Hypertension.","volume":"11","author":"Gnanenthiran","year":"2022","journal-title":"J Am Heart Assoc"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:05:35Z","timestamp":1746324335000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":29,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033904","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}